The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc’s Descovy to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men. The approval does not include use of the drug by women to prevent HIV infection. Descovy, a combination drug, was approved in 2016 to treat people already infected with HIV. …read more
Source:: Yahoo Finance
